Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P04637 (
p53
)
77,613
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Pleomorphic rhabdomyosarcoma
is the most common variant of this tumour in adults and has a very poor outcome. Two genes which are known to play a role in rhabdomyosarcoma development are KRas and
p53
. In the majority of human tumours,
p53
abnormalities are point mutations that result in the expression of a mutant form of the protein. It is now hypothesized that these mutant forms of
p53
may be playing an oncogenic role, over and above simple loss of the wild-type function. In this study, we use Cre-LoxP technology to develop a novel mouse model of rhabdomyosarcoma, crossing mice expressing a common KRas mutation (G12V) with mice that either lose
p53
expression or express a mutant form of
p53
. We use this model to explore the different effects of
p53
loss and mutation in the setting of an activating KRas mutation. We found that either complete loss of
p53
(
p53
(fl/fl)) or the expression of one mutant p53 allele with concomitant loss of the second allele (
p53
(R172H/+)) resulted in the rapid development of rhabdomyosarcoma in 15/16 and 19/19 mice, respectively. In contrast, there was a marked difference between mice which lose a single copy of
p53
(
p53
(fl/+)) and mice expressing a single copy of mutant p53 (
p53
(172H/+)). Fourteen out of 16
p53
(R172H/) mice developed rhabdomyosarcoma, compared with two out of 31
p53
(fl/+) mice. As a consequence of this,
p53
(fl/+) mice had a median lifespan nearly double that of the
p53
(R172H/+) mice. To underline the enhanced effect of
p53
mutation in tumour progression, metastases were seen only in those mice which expressed the mutant form. These data demonstrate that mutant p53 can co-operate with activated, mutant KRas to influence tumourigenesis and metastatic potential, over and above simple loss of normal protein function.
...
PMID:p53 mutation and loss have different effects on tumourigenesis in a novel mouse model of pleomorphic rhabdomyosarcoma. 2082 51